Movement Alert|Recursion Pharmaceuticals, Inc. After-Hours Rise 5.14%, market focus remains on REC-4881 registrational trial prospects

Market Focus11-18 08:59

On November 18, Recursion Pharmaceuticals, Inc. rose 5.14% in After-Hours Trading, trading at $2.85 per share, with turnover of $1.1708 million.

The key catalyst cited in recent market updates is continued investor focus on the timing of REC-4881’s registrational trial and the scope for valuation recovery following updated clinical data.

Recent disclosures said updated Phase 1b/2 TUPELO results showed REC-4881 delivered deeper and more durable reductions in polyp burden in familial adenomatous polyposis, with activity across the GI tract and a relatively clean safety profile that supports advancing toward a registrational study. Separately, the company reported quarterly revenue of $18.552 million, above the $14.783 million consensus estimate, while EPS was a loss of $0.22.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment